The launch time and market response of Lemborexant in China

Lemborexant (Lemborexant, trade name: Daweike), as a new type of insomnia treatment drug, has been officially launched in China, with a specification of 5 mg, 14 tablets, 2 plates. This listing marks the country’s gradual integration with international standards in the introduction of innovative sleep drugs. Compared with overseas markets, the introduction of Doveco in China provides patients with a new choice in addition to benzodiazepines and antihistamines, especially suitable for patients with long-term sleep disorder management.

In terms of market response, due to its innovative mechanism, high tolerability, and good compliance, domestic doctors and patients have paid high attention to Lebrasin. Especially for patients who have difficulty falling asleep and frequent nighttime awakenings, Darvec provides a safe and sustainable therapeutic experience. Some overseas clinical experiences show that the drug is effective in improving the speed of falling asleep and prolonging sleep time without affecting alertness and cognitive function the next day. This feature provides a reference for domestic patients.

However, currently, Davico has not been included in medical insurance, and price information is relatively limited, so initial use may be affected by economic factors. Domestic drug promotion strategies mainly rely on professional medical institutions and sleep specialist clinics, and are guided by doctor prescriptions and patient education. Market feedback shows that patients have high evaluations of its non-dependence and good tolerance, and at the same time have practical experience of its sleep improvement effect, which lays the foundation for its subsequent market expansion.

Overall, the domestic launch of Lebrasant not only provides new options for insomnia patients, but also promotes the update of clinical practice in sleep medicine. In the future, with the accumulation of clinical application data and potential inclusion in medical insurance, its market acceptance is expected to further increase and it will become an important drug for the treatment of chronic insomnia.

Reference materials:https://medlineplus.gov/druginfo/meds/a620039.html